Skip to main content

Table 1 Baseline characteristics of DLBCL patients completed 3 cycles of (R)-CHOP chemotherapy

From: Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP

  All patients No-AISC AISC P-value
N = 70 N = 44 N = 26
Age (year) 55.47 ± 13.63 55.50 ± 14.86 55.42 ± 11.54 0.982
Male/female (n) 33/37 20/24 13/13 0.713
BMI (kg/m2) 22.85 ± 3.31 22.12 ± 3.20 24.10 ± 3.18 0.014
Smoking(%) 17 (24.29) 7 (15.91) 10 (38.46) 0.033
GLS (-%) 20.04 ± 2.24 19.73 ± 2.29 20.58 ± 2.08 0.125
E (cm/s) 67.79 ± 13.01 66.01 ± 11.47 70.81 ± 15.01 0.137
e’(cm/s) 7.27 ± 2.03 6.92 ± 1.98 7.85 ± 2.02 0.067
LDL-C (mmol/L) 2.56 ± 0.77 2.42 ± 0.68 2.80 ± 0.85 0.046
NT-proBNP (ng/L) 54.00 (31.00, 127.00) 70.50 (32.25, 132.25) 41.50 (24.25, 76.50) 0.070
TC (mmol/L) 4.19 ± 0.93 4.07 ± 0.86 4.39 ± 1.02 0.168
TG (mmol/L) 1.36 (1.02, 1.68) 1.25 (0.91, 1.55) 1.54 (1.27, 1.92) 0.009
  1. Values are expressed as mean ± standard deviation, n (%), or median (Q1-Q3). Bold values indicate statistical significance (P < 0.05)
  2. AISC Anthracycline-induced subclinical cardiotoxicity, BMI Body mass index, DLBCL Diffuse large-B cell lymphoma, E mitral inflow E velocity, e’ mitral e’ velocity, GLS Global longitudinal peak systolic strain, LDL-C Low-density lipoprotein cholesterol, NT-proBNP N terminal-pro brain natriuretic peptide, TC Total triglyceride, TG Total cholesterol